Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IBRS19182 / CAPItello-291 / Ajay Dhakal

Research Question:
What is the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with advanced breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy?

Basic Study Information

Purpose:
Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Location: University of Rochester Medical Center
Study Reference #: IBRS19182

Lead Researcher (Principal Investigator)

Lead Researcher:  Ajay Dhakal

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Return to Search